Importance: Early experience with intraocular, non-biodegradable fluocinolone acetonide (FAc) (0.2 µg/day) implant (ILUVIEN ® ), comparing visual function before and after treatment in an insufficiently responsive diabetic macular oedema (DMO) patient. Observations: This 62-yearold male patient with type 2 diabetes mellitus was first treated for DMO in 2004, when best corrected visual acuity (BCVA) was 0.8 for his right eye. He did not visit an ophthalmologist again until 2011 when BCVA had declined to 0.2. Three separate, monthly intravitreal (IV) ranibizumab injections and additional laser photocoagulation resulted in no improvement. Subsequently, 0.7 mg IV dexamethasone was administered, giving short-term DMO improvement. However, six further IV ranibizumab injections produced no effect and a combined injection of IV ranibizumab with 0.7 mg IV dexamethasone provided only short-term improvements. Following phacoemulsification, a 0.2 µg/day FAc implant was administered. Optical coherence tomography (OCT) indicated complete DMO regression after 3 weeks, sustained 6 months post-implant. BCVA improved to 0.25 and the patient reported greater vision-related quality of life. Intraocular pressure increased gradually but resolved with daily timolol/dorzolamide and tafluoprost eye drops. Conclusions and relevance: In a DMO patient showing insufficient response to IV ranibizumab and dexamethasone injections, FAc implant provided an effective therapeutic option with manageable side effects.
Diabetic retinopathy (DR) is the most common cause of moderate-tosevere visual impairment among working class adults. 1 Diabetic macular oedema (DMO), a common manifestation of DR, causes central vision loss, 2 and is a consequence of vascular inner blood-retinal barrier breakdown. 3 Global prevalence of DR among diabetic individuals is approximately 35 %, with DMO present in 6.8 %. 4 DMO is difficult to manage due to its chronicity. Historically, the standard of care was laser therapy; however, a large number of patients continued to lose vision, 1, 5 with significant vision recovery in only 15 % of treated patients. 11 In particular, patients presenting with diffuse DMO, where causal vascular abnormalities are not restricted to discrete foci, are likely to be refractory to laser therapy. 6 Given the proportion of patients with DMO refractory to laser therapy, new therapies providing sustained benefit are needed. 7 Alternative DMO treatments are evolving rapidly, with a number demonstrating promise in preventing visual acuity (VA) deterioration and improving vision. 11 Patients receiving non-protocol treatments were included. Patients were eligible for rescue laser after 6 weeks or retreatment with assigned therapy after 1 year.
Three-year treatment with 0.2 μg/day FAc improved BCVA in 34.0 % of chronic (≥3 years median duration) DMO patients compared with 13.4 % sham-treated patients, with mean changes in BCVA score of 7.6 and 1.8 letters, respectively. 7 CFT rapidly and substantially decreased from baseline in both FAc-and sham-treated chronic DMO patients. 7 Although at 36 months FAc implant patients needed cataract surgery more frequently than those patients who received sham injection, their post-surgery visual benefit was similar to subjects pseudophakic at baseline. Surgery to manage elevated intraocular pressure (IOP) was also more frequent for FAc-treated patients compared with sham (4.8 % versus 0.5 %). Lost to follow-up until 2011, BCVA had deteriorated to 0.2 in both eyes.
From 2011, the patient's response to therapy was evaluated using BCVA and CFT measured using spectral optical coherence tomography (OCT).
IV ranibizumab injection in 2011 gave no benefit for LE BCVA and given the lack of response to therapy and the long history of DMO, no further treatment was administered to the LE at this time.
Three separate, monthly IV ranibizumab injections in the RE, administered between September and November 2011, did not improve BCVA and focal laser photocoagulation was provided: IOP was 16 mmHg. A 0.7 mg dexamethasone implant in December 2011 produced short-term CFT decrease (442 μm to 347 μm) without improving BCVA (see Figures 1A and B) . Six further IV ranibizumab injections over 8 months had no effect on visual outcomes, with CFT worsening (347 to 488 μm; Figure 1B ) and IOP increasing 
Management of Intraocular Pressure
Following 0.2 μg/day FAc implantation, gradual elevation in IOP was observed over the first 2 months (from 16 mmHg to 28 mmHg). This was resolved with daily dorzolamide/timolol eye drops (21 mmHg at 6 months). In February 2014, tafluoprost eye drops were prescribed in addition to further reduce the IOP. The daily application of eye drops was not a concern for the patient and did not interfere with his quality of life.
Comments
Randomized clinical trials indicate intraocular vascular endothelial growth factor (VEGF) inhibition provides significant BCVA and CFT improvements in patients with DMO. 12 While this is a widely used therapeutic strategy in patients refractory to laser therapy, other studies have shown that anti-VEGF therapy alone is not effective in all patients with DMO, 13 as shown in this case.
The Fluocinolone Acetonide for Macular Edema (FAME) study demonstrated a single IV injection FAc implant can provide significant, long-term BCVA and CFT improvements in chronic DMO patients. 7, 14 In this case study, a single 0.2 μg/day FAc implant improved BCVA and CFT when the patient was insufficiently responsive to all previous treatments, including ranibizumab, laser photocoagulation Figure 1) . FAc implant gave marked improvements of BCVA and with complete regression of MO after 3 weeks, consistent with the FAME study, 7 which were still apparent after 6 months. Additional anti-VEGF therapy in February 2014 appeared to increase these benefits, reflecting the multifactorial nature of DMO. 16 IOP was elevated with 0.2 µg/day FAc, but was effectively managed by twice-daily dorzolamide/timolol and once-daily tafluprost eye drops. Given the lack of response to other currently available therapies, and the improvement in vision, the benefit-risk ratio following the 0.2 μg/day FAc implantation is positive for this patient and highlights the importance of early intervention when a patient is responding insufficiently, or not responding, to anti-VEGF therapy. The current outcomes also suggest that to achieve functional benefits from DMO resolution (e.g. BCVA 
